Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: a retrospective analysis

Ergun Y., Ozdemir N. Y. , Guner E. K. , Esin E., ŞENDUR M. A. N. , Koksoy E. B. , ...More

JOURNAL OF BUON, vol.23, 2018 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 23
  • Publication Date: 2018
  • Title of Journal : JOURNAL OF BUON


Purpose: Gemcitabine is among the standard first-line agents for the treatment of metastatic pancreatic cancer. However, as the median survival with gemcitabine monotherapy is 6 months, different combinations are being studied for better, prolonged survival. In this multicenter study, we aimed to compare the results of gemcitabine monotherapy with those of gemcitabine and cisplatin combination therapy as first-line treatments for metastatic pancreatic cancer.